1Institute for Veterinary Medical Research, Centre for Agricultural Research, Hungária krt. 21, H-1143, Budapest, Hungary.
2SCG Diagnostics Ltd., Délegyháza, Hungary.
Acta Vet Hung. 2021 Jul 16;69(2):110-115. doi: 10.1556/004.2021.00026.
The control of Mycoplasma hyorhinis infection relies mainly on antimicrobial therapy. However, the antibiotic susceptibility testing of the bacteria is usually not performed before applying the treatment, and thus therapeutic failures are not uncommon. In the case of M. hyorhinis, several antibiotic-resistance-related single nucleotide polymorphisms (SNPs) are known but assays for their detection have not been described yet. The aims of the present study were to investigate macrolide- and lincomycin-resistance-related SNPs in Hungarian M. hyorhinis isolates and to develop mismatch amplification mutation assays (MAMA) to detect the identified resistance markers. Minimal inhibitory concentrations (MIC) of different drugs and whole genome sequences of 37 M. hyorhinis isolates were used to find the resistance-related mutations. One MAMA assay was designed to detect the mutation of the 23S rRNA gene at nucleotide position 2058 (Escherichia coli numbering). For further evaluation, the assay was challenged with 17 additional isolates with available MIC data and 15 DNA samples from clinical specimens. The genotypes of the samples were in line with the MIC test results. The developed assay supports the practice of targeted antibiotic usage; hence it may indirectly reduce some bacterial resistance-related public health concerns.
控制支原体感染主要依赖于抗菌治疗。然而，在应用治疗之前通常不会对细菌进行抗生素敏感性测试，因此治疗失败并不罕见。在支原体的情况下，已知有几个与抗生素耐药性相关的单核苷酸多态性（SNPs），但尚未描述用于检测它们的检测方法。本研究的目的是调查匈牙利支原体分离株中与大环内酯类和林可霉素相关的 SNPs，并开发用于检测鉴定的耐药标记的错配扩增突变分析（MAMA）。使用不同药物的最小抑菌浓度（MIC）和 37 株支原体分离株的全基因组序列来寻找与耐药相关的突变。设计了一种 MAMA 检测来检测 23S rRNA 基因在核苷酸位置 2058（大肠杆菌编号）的突变。为了进一步评估，该检测方法还使用了 17 个具有可用 MIC 数据的额外分离株和 15 个来自临床标本的 DNA 样本进行了检测。样本的基因型与 MIC 检测结果一致。开发的检测方法支持靶向抗生素使用的实践；因此，它可能会间接减少一些与细菌耐药性相关的公共卫生问题。
